Ser9
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser9  -  SET iso2 (human)

Site Information
sAPAAkVsKkELNsN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 6308300

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 7 ) , immunoassay ( 1 , 4 ) , immunoprecipitation ( 3 , 4 , 7 ) , mass spectrometry ( 2 , 5 ) , mass spectrometry (in vitro) ( 6 ) , mutation of modification site ( 1 , 3 , 4 , 6 ) , peptide sequencing ( 7 ) , phospho-antibody ( 4 ) , phosphoamino acid analysis ( 7 ) , western blotting ( 1 , 4 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
PPP2CA (human) ( 4 )
Putative in vivo kinases:
CK2A1 (human) ( 4 ) , PIK3CG (human) ( 6 )
Kinases, in vitro:
PIK3CG (human) ( 6 )
Treatments:
AG490 ( 3 ) , AS_604850 ( 3 ) , calphostin_C ( 3 ) , fedratinib ( 3 ) , fingolimod ( 3 ) , hispidin ( 3 ) , JAK_inhibitor_I ( 3 ) , LY294002 ( 3 ) , PD98059 ( 3 ) , PKC412 ( 3 ) , wortmannin ( 6 )

Downstream Regulation
Effects of modification on SET iso2:
enzymatic activity, inhibited ( 3 , 4 ) , intracellular localization ( 4 ) , molecular association, regulation ( 4 , 6 ) , phosphorylation ( 4 , 6 ) , receptor desensitization, induced ( 6 )
Effects of modification on biological processes:
signaling pathway regulation ( 3 , 6 )
Induce interaction with:
PPP2CA (human) ( 6 )
Inhibit interaction with:
KPNA1 (human) ( 4 ) , KPNB1 (human) ( 4 )

Disease / Diagnostics Relevance
Relevant diseases:
Alzheimer's disease ( 4 )

References 

1

De Palma RM, et al. (2019) The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction. FASEB J, fj201802264R
30917007   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Oaks JJ, et al. (2013) Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 122, 1923-34
23926298   Curated Info

4

Yu G, et al. (2013) Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease. Neurobiol Aging 34, 1748-58
23374587   Curated Info

5

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

6

Vasudevan NT, et al. (2011) Inhibition of Protein Phosphatase 2A Activity by PI3Kγ Regulates β-Adrenergic Receptor Function. Mol Cell 41, 636-48
21419339   Curated Info

7

Adachi Y, Pavlakis GN, Copeland TD (1994) Identification of in vivo phosphorylation sites of SET, a nuclear phosphoprotein encoded by the translocation breakpoint in acute undifferentiated leukemia. FEBS Lett 340, 231-5
8131851   Curated Info